Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback